Cross-Knorr, S., Lu, S., Perez, K., Guevara, S., Brilliant, K., Pisano, C., . . . Chatterjee, D. (2013). RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BioMed Central.
Citação norma ChicagoCross-Knorr, Sam, Shaolei Lu, Kimberly Perez, Sara Guevara, Kate Brilliant, Claudio Pisano, Peter J. Quesenberry, Murray B. Resnick, and Devasis Chatterjee. RKIP Phosphorylation and STAT3 Activation Is Inhibited By Oxaliplatin and Camptothecin and Are Associated With Poor Prognosis in Stage II Colon Cancer Patients. BioMed Central, 2013.
Citação norma MLACross-Knorr, Sam, et al. RKIP Phosphorylation and STAT3 Activation Is Inhibited By Oxaliplatin and Camptothecin and Are Associated With Poor Prognosis in Stage II Colon Cancer Patients. BioMed Central, 2013.